Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $36.33

Vir Biotechnology, Inc. (NASDAQ:VIR) has been given an average rating of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $36.33.

Several research firms have weighed in on VIR. Barclays lowered their price objective on Vir Biotechnology from $59.00 to $41.00 and set an “overweight” rating on the stock in a research report on Friday, July 21st. Bank of America cut Vir Biotechnology from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $23.00 to $14.00 in a research report on Friday, September 8th. HC Wainwright lowered their price objective on Vir Biotechnology from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, August 7th. Morgan Stanley lowered their price objective on Vir Biotechnology from $27.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Friday, July 21st. Finally, Needham & Company LLC lowered their price objective on Vir Biotechnology from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently made changes to their positions in the company. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Vir Biotechnology by 87,228.6% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 32,002,440 shares of the company’s stock valued at $785,020,000 after purchasing an additional 31,965,794 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Vir Biotechnology by 21.1% during the third quarter. Vanguard Group Inc. now owns 9,928,416 shares of the company’s stock worth $191,420,000 after acquiring an additional 1,731,172 shares during the last quarter. State Street Corp raised its position in shares of Vir Biotechnology by 5.6% during the third quarter. State Street Corp now owns 5,830,417 shares of the company’s stock worth $112,410,000 after acquiring an additional 311,279 shares during the last quarter. Temasek Holdings Private Ltd raised its position in shares of Vir Biotechnology by 1.8% during the first quarter. Temasek Holdings Private Ltd now owns 5,814,972 shares of the company’s stock worth $135,314,000 after acquiring an additional 104,462 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Vir Biotechnology by 1.7% during the first quarter. BlackRock Inc. now owns 5,396,184 shares of the company’s stock worth $138,790,000 after acquiring an additional 88,135 shares during the last quarter. 67.05% of the stock is owned by institutional investors and hedge funds.

Vir Biotechnology Trading Up 0.5 %

VIR opened at $9.69 on Friday. Vir Biotechnology has a 1-year low of $7.72 and a 1-year high of $31.55. The stock’s fifty day simple moving average is $8.94 and its 200 day simple moving average is $16.37. The stock has a market cap of $1.30 billion, a PE ratio of -2.16 and a beta of 0.31.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.